Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867126 · ClinicalTrials.gov registry record · Early Phase 1
Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT00867126 is a Early Phase 1 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 6 participants.
The verdict
NCT00867126, a Early Phase 1 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Pioglitazone may slow the growth of tumor cells and may be an effective treatment for pancreatic cancer. PURPOSE: This phase I trial is studying how well pioglitazone works as second-line therapy in treating patients with metastatic pancreatic cancer that progressed after treatment with gemcitabine.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- PROCEDURE quality-of-life assessment
- DRUG pioglitazone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-03-02 |
| Est. Completion | 2012-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00867126
The ClinicalTrials.gov registry entry for NCT00867126 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00867126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00867126 about?
NCT00867126 is a clinical study titled "Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine". RATIONALE: Pioglitazone may slow the growth of tumor cells and may be an effective treatment for pancreatic cancer. PURPOSE: This phase I trial is studying how well pioglitazone works as second-line therapy in treating patients with metastatic pancreatic cancer that progressed after treatment with ...
What is the current status of trial NCT00867126?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2009-03-02. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00867126?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), quality-of-life assessment (PROCEDURE), pioglitazone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00867126?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.